Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 114, Issue 7, Pages 1660-1665
Publisher
Proceedings of the National Academy of Sciences
Online
2017-01-31
DOI
10.1073/pnas.1614775114
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification and Characterization of the Dermal Panniculus Carnosus Muscle Stem Cells
- (2016) Neia Naldaiz-Gastesi et al. Stem Cell Reports
- Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing
- (2015) Shin-Heng Chiou et al. GENES & DEVELOPMENT
- Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection
- (2015) Xiquan Liang et al. JOURNAL OF BIOTECHNOLOGY
- Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy
- (2015) C. Long et al. SCIENCE
- In vivo gene editing in dystrophic mouse muscle and muscle stem cells
- (2015) M. Tabebordbar et al. SCIENCE
- In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
- (2015) C. E. Nelson et al. SCIENCE
- In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
- (2014) Danilo Maddalo et al. NATURE
- In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9
- (2014) Lukasz Swiech et al. NATURE BIOTECHNOLOGY
- Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo
- (2014) John A Zuris et al. NATURE BIOTECHNOLOGY
- Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
- (2014) Hao Yin et al. NATURE BIOTECHNOLOGY
- The new frontier of genome engineering with CRISPR-Cas9
- (2014) J. A. Doudna et al. SCIENCE
- Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa
- (2014) D. Wenzel et al. Science Translational Medicine
- Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa
- (2014) V. Sebastiano et al. Science Translational Medicine
- Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa
- (2014) N. Umegaki-Arao et al. Science Translational Medicine
- Induced Pluripotent Stem Cells in Dermatology: Potentials, Advances, and Limitations
- (2014) G. Bilousova et al. Cold Spring Harbor Perspectives in Medicine
- RNA-Guided Human Genome Engineering via Cas9
- (2013) P. Mali et al. SCIENCE
- Multiplex Genome Engineering Using CRISPR/Cas Systems
- (2013) L. Cong et al. SCIENCE
- Bone Marrow Stem Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa
- (2010) Maija Kiuru et al. DERMATOLOGIC CLINICS
- Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa
- (2010) John E. Wagner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dystrophic Epidermolysis Bullosa: Pathogenesis and Clinical Features
- (2009) Leena Bruckner-Tuderman DERMATOLOGIC CLINICS
- Potential of Fibroblast Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa
- (2008) Tracy Wong et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Injection of Recombinant Human Type VII Collagen Corrects the Disease Phenotype in a Murine Model of Dystrophic Epidermolysis Bullosa
- (2008) Jennifer Remington et al. MOLECULAR THERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More